| 0 (0%) | 12-27 04:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.26 | 1-year : | 4.97 |
| Resists | First : | 3.65 | Second : | 4.26 |
| Pivot price | 3.41 |
|||
| Supports | First : | 3.13 | Second : | 2.8 |
| MAs | MA(5) : | 3.44 |
MA(20) : | 3.38 |
| MA(100) : | 3.34 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 65.4 |
D(3) : | 64.1 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 13.3 | Low : | 2.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RCKT ] has closed below upper band by 35.0%. Bollinger Bands are 41.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.55 - 3.56 | 3.56 - 3.58 |
| Low: | 3.38 - 3.4 | 3.4 - 3.42 |
| Close: | 3.45 - 3.48 | 3.48 - 3.51 |
Fri, 26 Dec 2025
Rocket Pharmaceuticals: Upside On LAD-I Approval And Amended Danon Program - Seeking Alpha
Sat, 20 Dec 2025
Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at TD Cowen - MarketBeat
Mon, 15 Dec 2025
Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position - Yahoo Finance
Sun, 14 Dec 2025
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Tue, 25 Nov 2025
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
Tue, 18 Nov 2025
New Analyst Forecast: $RCKT Given $263.0 Price Target | RCKT Stock News - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 108 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 11,030 (K) |
| Shares Short P.Month | 11,030 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -202 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -1.55 |
| PEG Ratio | 0 |
| Price to Book value | 1.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|